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Abstract: Autoimmune diseases are a heterogeneous
group of diseases characterized by immune reactions
against either a major or a limited number of the bodies
own autoantigens, causing inﬂammation and damage to
tissues and organs. Thus, identiﬁcation of autoantigens
is an important ﬁrst step to understanding autoimmune
diseases. Here we demonstrate a simple screening method
for identiﬁcation of autoantigens reacting with patient
serum antibodies by combination of an N-terminal bioti-
nylated protein library (BPL), produced using a wheat cell-
free protein production system, and a commercially
available luminescence system. Optimization studies us-
ing well-characterized autoantigens showed speciﬁc in-
teractions between N-terminal biotinylated proteins and
antibody that were sensitively detected under homoge-
neous reaction conditions. In this optimized assay, 1 µL
of the translation mixture expressing the biotinylated
proteins produced signiﬁcant luminescence signal by
addition of diluted serum between 1:500 and 1:10 000 in
25 µL of reaction volume. For the BPL construction, 214
mouse genes, consisting of 103 well-known autoantigens
and 111 genes in the mouse autoimmune susceptibility
loci, and the sera of MRL/lpr mouse were used as an
autoimmune model. By this screening method, 25 well-
known autoantigens and 71 proteins in the loci were
identiﬁed as autoantigen proteins speciﬁcally reacting
with sera antibodies. Cross-referencing with the Gene
Ontology Database, 26 and 38 of autoantigen proteins
were predicted to have nuclear localization and identiﬁed
as membrane and/or extracellular proteins. The immune
reaction of six randomly selected proteins was conﬁrmed
by immunoprecipitation and/or immunoblot analyses.
Interestingly, three autoantigen proteins were recognized
by immunoprecipitation but not by immunoblot analysis.
These results suggest that the BPL-based method could
provide a simple system for screening of autoantigen
proteins and would help with identiﬁcation of autoanti-
gen proteins reacting with antibodies that recognize
folded proteins, rather than denatured or unfolded forms.
Keywords: autoantigen • autoimmunity • biomarker • cell-
free protein production • Gene Ontology • high-throughput
screening • MRL/lpr mouse • proteomics
Introduction
Autoimmune diseases are generally characterized by the
body’s immune responses being directed against its own
tissues, causing prolonged inﬂammation and subsequent tissue
destruction.
1 A hallmark of autoimmune diseases is the pro-
duction of autoantibodies such as antinuclear, anti-Sm and
anti-dsDNA in systemic lupus erythematosus (SLE),
2 and the
presence of RF, hnRNP A2 and calpastatin in rheumatoid
arthritis (RA).
3 However, there are still a lot of autoimmune
diseases for which antibodies have not been identiﬁed.
2 To
understand the molecular mechanisms in autoimmune dis-
eases, it is important to identify the relevant autoantigens, and
moreover, they could be pathogenic in these diseases. It is
widely hypothesized that proteins are the major antigenic
targets associated with autoimmune diseases.
2 Therefore,
development of methods that allow large-scale screening of
autoantigen proteins is indispensable for elucidation and
diagnosis of the autoimmune diseases.
To date, autoantigen proteins have been detected as anti-
genic molecules that are recognized by humoral antibodies,
including those in serum.
2 The large-scale screening of au-
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been carried out by mainly three technologies: serological
proteome analysis (SERPA), serological expression cloning
(SEREX) and protein microarray.
4 The utility of SERPA and
SEREX for this screening is limited because particular cells and
tissues are generally used as antigen resources in these systems
and they are dependent on artiﬁcial membranes for immuno-
blotting which do not maintain native protein structure.
5
Recent advances in protein microarray technology have allowed
large-scale screening of autoantigens reacting with the sera of
patients suffering from autoimmune disorders and cancer.
5-7
However, protein microarray is not yet a commonly used
biochemical tool for screening.
8 One issue with protein mi-
croarrays is that puriﬁed recombinant proteins are required,
which demonstrate batch-to-batch variation and limited stabil-
ity and shelf life.
5 Additionally, it is difﬁcult to maintain the
functional form of a protein after their immobilization on a
microplate. Many proteins needed to be appropriately oriented
for proper functioning.
9 In fact, a number of spotted autoan-
tigens were not always detectable with planar arrays, presum-
ably due to loss of three-dimensional structures, steric inter-
ference or electrostatic repulsion.
6
In this work, we developed a novel autoantigen protein
screening method that overcame the following issues high-
lighted above: (1) utilization of a high-throughput and genome-
wide protein expression system, (2) speciﬁc protein labeling
for assay using unpuriﬁed protein samples and (3) high-
throughput detection system of properly folded antigen. To-
ward the ﬁrst, we recently developed an automated protein
production robot utilizing a high-throughput wheat embryo
derived cell-free protein production system.
10,11 The combina-
tion of an automatic cell-free protein production system and
the full-length cDNA allowed for facile construction of a robust
protein library.
12 To enhance the utility of the library, per the
second issue above, speciﬁc labeling of each protein is required
for efﬁcient detection. We selected biotin as the labeling
compound because it is readily available and demonstrates
high speciﬁcity for streptavidin binding. The biotinylated
protein library (BPL) was constructed using target proteins
fused to a biotin ligation site (bls), and expression was
performed in the presence of biotin and biotin ligase (BirA).
13
BirA from Escherichia coli speciﬁcally conjugates a single biotin
on the bls. This method was compatible with our high-
throughput automated platform. To address the third issue, we
selected the luminescent high-throughput protein-protein
interaction detection system AlphaScreen.
14,15 This method can
directly recognize biotinylated protein in the translation mix-
ture without puriﬁcation and the use of any potential protein
denaturants allowing for antibody detection of natively folded
antigens.
15 In this work, we demonstrate a simple BPL-based
method for screening of autoantigen proteins reacting with the
sera of an autoimmune disease model mouse, MRL/Mp-lpr/
lpr (MRL/lpr), and the detection of the autoantigen proteins
by immunoprecipitation, rather than immunoblotting methods
often accompanied by protein denaturation.
Materials and Methods
General. The following procedures have been either de-
scribed in detail or cited previously:
10,16 generation of DNA
template by polymerase chain reaction (PCR) using “split-
primer”; synthesis of mRNA and protein in parallel; estimation
of the amounts of synthesized proteins by densitometric
scanning of the Coomassie brilliant blue (CBB)-stained bands
or by autoradiography. The wheat germ extract was purchased
from Cell-Free Science Co. (Yokohama, Japan). Anti-p53 mono-
clonal antibody (D01) was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse serum for mouse immu-
noglobulin in Figure 1 was purchased from Calbiochem
(Darmstadt, Germany). Other reagents used in this study were
described previously.
10,15
Serum Samples. MRL/lpr mice were originally purchased
from the Jackson Laboratory (Bar Harbor, ME). All of the mice
used in this paper were maintained in clean rooms at the
Animal Research Institute, School of Medicine, Ehime Univer-
sity. Sera of female mice were collected from 15 mice and
pooled and stocked in -20 °C until use. All experiments were
done according to the Guidelines for the Care and Use of
Laboratory Animals at Ehime University.
DNA Template Construction for the BPL. Functional an-
notation of mouse (FANTOM) as a mouse full-length cDNA
resource is purchased from a company (Danaform, Tokyo,
Japan). The DNA templates for transcription were constructed
by “split-primer” PCR technique described previous reports.
10,17
The ﬁrst PCR was ampliﬁed with 10 nM of each of the following
primers: a gene speciﬁc primer, 5′- CCACCCACCACCACCAAT-
Gnnnnnnnnnnnnnnnnnnn (n denotes the coding region of the
target gene), and AODA2303 (5′-GTCAGACCCCGTAGAAAAGA)
or AODS (5′-TTTCTACGGGGTCTGACGCT). The second PCR
products for protein synthesis were constructed with 100 nM
SPu 5′-GCGTAGCATTTAGGTGACACT, 1 nM deSP6E02bls-S1
(5′-GGTGACACTATAGAACTCACCTATCTCTCTACACAAAACA-
TTTCCCTACATACAACTTTCAACTTCCTATTATGGGCCTGAAC-
GACATCTTCGAGGCCCAGAAGATCGAGTGGCACGAACTCCA-
CCCACCACCACCAATG) and 100 nM AODA2303 or AODS. By
this “split-primer” PCR, the bls was fused onto the N-terminals
of all the genes for protein biotinylation.
13
Construction of the BPL by the Cell-Free Protein Synthesis
System. Cell-free construction of the BPL is based on the
previously described bilayer diffusion system in which 1 µL (50
ng) crude cell-free expressed BirA was added to the translation
layer and 500 nM D-biotin (Nacalai Tesque, Kyoto, Japan) was
added to both the translation and substrate layers.
13,18 In vitro
transcription and cell-free protein synthesis for the BPL were
carried out using the GenDecoder1000 robotic synthesizer
(CellFree Sciences Co.) as previously described.
17,19
Detection of Biotinylated Protein-Antibody Reaction by
Luminescence Method. The AlphaScreen assay was performed
according to the manufacture’s protocol (PerkinElmer Life and
Analytical Sciences, Boston, MA). Reactions were carried out
in 25 µL of reaction volume in 384-well Optiwell microtiter
plates (PerkinElmer Life and Analytical Sciences). For the
antigen-autoantibody reaction, the translation mixture ex-
pressing the biotinylated protein was mixed with MRL/lpr
mouse serum diluted 1:600 in 15 µL of reaction buffer [100 mM
Tris-HCl (pH 8.0), 0.01% (v/v) Tween-20 and 0.1% (w/v) bovine
serum albumin] and incubated at 26 °C for 30 min. Subse-
quently, 10 µL of streptavidin-coated donor beads and protein
A-conjugated acceptor beads (PerkinElmer Life and Analytical
Sciences) were added to a ﬁnal concentration of 20 µg/mL per
well and incubated at 26 °Cf o r1hi nadark box. Fluorescence
emission was measured with the EnVision plate reader (Perki-
nElmer Life and Analytical Sciences), and the resultant data
were analyzed using the AlphaScreen detection program. All
repetitive mechanical procedures were performed by a Biomek
FX robotic workstation (Beckman Coulter, Fullerton, CA).
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ﬁed using streptavidin-coated beads (Streptavidin Sepharose
High Performance, GE Healthcare, Buckinghamshire, U.K.).
Translation mixtures (150 µL) including biotinylated proteins
were mixed with 10 µL of streptavidin-coated beads for 30 min.
The resin was washed three times with PBS buffer and then
boiled in 15 µL of SDS sample buffer (50 mM Tris-HCl pH 6.8,
2% SDS, 10% glycerol and 0.2% bromophenol blue). After
separation by 12.5% SDS-PAGE, the proteins were transferred
to PVDF membrane (Millipore, Bedford, MA) by semidry
blotting. The membrane was soaked in PBS containing 5% (w/
v) skim milk for 1 h and then incubated with serum diluted
1:200 in PBS containing 0.1% (v/v) Tween 20 (PBST) for 1 h.
After washing three times in PBST, it was incubated in PBS
including goat-antimouse IgG-HRP antibody (GE Healthcare)
diluted 1:10 000 for 30 min. After washing three times in PBST,
the blots were detected by the ECL plus detection system (GE
Healthcare) by using Typhoon 9400 imaging system (GE
Healthcare) according to the manufacturer’s protocol.
Immunoprecipitation. Fifty microliters of translation mix-
ture expressing biotinylated proteins were incubated in 50 µL
of IP buffer [PBS containing 0.1% (w/v) BSA, 0.15% (v/v) Tween
20] with 1 µL of undiluted serum overnight at 4 °C. Immobilized
Protein A sepharose (20 µL of 50% slurry, Protein A Sepharose
4 Fast Flow, GE Healthcare) in IP buffer was added to each
sample and incubated for 60 min at 4 °C. After centrifugation
for 1 min at 900× g, samples were washed three times with IP
buffer and then boiled for 5 min in SDS sample buffer. After
separation by 12.5% SDS-PAGE, the samples were transferred
to a Hybond-LFP PVDF membrane (GE Healthcare). After
blocking with 5% (w/v) skim milk in PBS overnight at 4 °C, the
membranes were soaked in PBS buffer containing 10 µg/mL
streptavidin Alexa Fluor 488 conjugate (Alexa488-STA) (Invit-
rogen, Carlsbad, CA) and were washed three times with PBST.
The biotinylated proteins on membrane were detected by
Typhoon 9400 imaging system (GE Healthcare) according to
the manufacturer’s protocol.
Results
Sensitivity and Speciﬁcity for Detection of Antigen-Antibody
Interaction Using Biotinylated p53 Protein. We adapted that
AlphaScreen technology toward detecting interactions between
antigen protein and antibody. To validate this technique, we
used p53 protein, a well-characterized antigen protein.
20 Bi-
otinylated or nonbiotinylated recombinant p53 and biotinylated
recombinant dihydrofolate reductase (DHFR), serving as nega-
tive control, were synthesized by the wheat cell-free system
(Figure 1A). For the analysis of antigen protein-antibody
interaction, the translation mixture was used without any
puriﬁcation. In the AlphaScreen system, interaction of the
biotinylated protein and antibody in sera results in a biotiny-
lated protein-antibody complex that is captured simulta-
neously by the streptavidin-coated donor beads and the protein
Figure 1. Sensitivity and speciﬁcity for detection of biotinylated p53 protein-antibody complex. (A) Biotinylated p53 (lane 1) and
dihydrofolate reductase (DHFR) (lane 2) was detected by immunoblotting analysis using Alexa488-STA. M indicates protein molecular
weight marker. (B) Schematic diagram of detection of biotinylated protein-antibody interaction by luminescence analysis. When a
biotinylated protein and antibody interact (upper panel), Protein A-conjugated acceptor beads bound to antibody and streptavidin
(STA)-coated donor beads bound to biotinylated protein are in close proximity. Upon excitation at 680 nm, a singlet oxygen is generated
by the donor beads, transferred to the acceptor beads within 200 nm, and the resultant reaction emits light at 520-620 nm. This
emission is measured using an EnVision. (C) Detection sensitivity of the antibody concentration measured by luminescence analysis.
Translation mixture (1 µL) expressing biotinylated or nonbiotinylated p53 protein and biotinylated DHFR were incubated with various
concentration of monoclonal antibody from 5 × 10-3 to 5 × 102 pg/µL. (D) Biotinylated protein-antibody complex by interaction between
biotinylated p53 protein and the monoclonal antibody in the presence of mouse serum was detected by luminescence analysis. (E)
Minimum IgG amount in the presence of mouse serum to detect biotinylated p53 proteins. The relative luminescence signals between
the speciﬁc luminescence and background signals indicated in the y-axis.
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acceptor and donor bead generates the luminescent signal
upon irradiation at 680 nm. This is illustrated in Figure 1B.
For biotinylation of the target protein, the N-terminus of the
target was fused to the bls, and the cell-free system was
supplemented with BirA and biotin.
13 This biotin ligation
method yields a biotin labeling on the bls, indicating a speciﬁc
recognition of the target protein by AlphaScreen. To investigate
the speciﬁcity and sensitivity of the antibody detection, transla-
tion mixtures expressing biotinylated or nonbiotinylated p53
protein were incubated with various concentrations of mono-
clonal antibody, ranging from 5 × 10-3 to 5 × 102 pg/µL. This
luminescence method speciﬁcally detected interaction of mon-
oclonal antibody and the biotinylated p53 from the unpuriﬁed
translation mixture, whereas nonbiotinylated p53 and bioti-
nylated DHFR did not produce a signiﬁcant luminescent signal
(Figure 1C). In this condition, the biotinylated p53 was detected
by anti-p53 antibody at concentrations as low as 0.5 pg/µL.
Next, we investigated whether this luminescence method could
detect the biotinylated protein-antibody complex in the pres-
ence of mouse serum. Translation mixture expressing biotiny-
lated p53 protein was incubated with various concentrations
of monoclonal antibody from 2 to 200 pg/µL and mouse
immunoglobulin from 0.4 to 40 ng/µL. Figure 1D showed that
this method could speciﬁcally detect the immunocomplex of
biotinylated p53 protein and monoclonal antibody in the
presence of an excess of mouse immunoglobulin. In addition,
comparison between the speciﬁc luminescence and back-
ground signals indicated that biotinylated p53 could be de-
tected at more than 0.05% of anti-p53 antibody in mouse serum
(Figure 1E). These results indicate that this system is a highly
speciﬁc and sensitive method for detection of interaction
between biotinylated recombinant protein and antibody in
whole serum.
Detection of Autoantibodies against Hars and LmnB2
Proteins in sera of MRL/lpr Mice. We next tested our protocol
for the well-characterized autoantigens histidyl-tRNA syn-
thetase (Hars)
21 and lamin B2 (LmnB2)
22 in the autoimmune
disease model mouse MRL/lpr.
23 To determine the assay
conditions using serum samples, biotinylated recombinant
Hars and LmnB2 proteins were used (Figure 2A) to detect
autoantibody in the sera of MRL/lpr mice. Cell-free synthesis
of biotinylated Hars and LmnB2 demonstrated yields of 820
and 600 nM, and 43.0 and 56.4% of biotinylation, indicating
biotinylated Hars and LmnB2 proteins were 354.4 and 338.5
nM, respectively. Various volumes (0.003 to 4 µL) of translation
mixture expressing biotinylated Hars or LmnB2 protein were
incubated with the serum of MRL/lpr mouse (ﬁnal 1:1000
dilution) in 25 µL of reaction volume (Figure 2B). Signiﬁcant
luminescent signals were observed at additions of biotinylated
Hars or LmnB2 proteins between 0.01 and 1 µL, which
corresponds to biotinylated protein concentrations between
0.14 and 14 nM or 0.13 and 13 nM, respectively. Also serum
dilutions between 1:500 and 1:10 000 produced high lumines-
cence signal in 25 µL of reaction volume using 1 µLo ft h e
translation mixtures (Figure 2C). These results mean that ﬁve
micro litter of serum and 200 µL of cell-free translation mixture
expressing biotinylated proteins would be sufﬁcient for 200
assays. Taken together, these results suggest that the lumines-
cence method using cell-free expressed biotinylated proteins
would be useful for screening the reaction of autoantigen
proteins with autoantibodies in serum.
Construction of the BPL by the Wheat Cell-Free Protein
Production System. It has long been thought that compre-
hensive screening using a protein library is a strong tool for
identiﬁcation of antigen proteins.
12,24,25 The scheme for the
BPL-based screening is shown in Figure 3A. To construct the
N-terminal BPL, we selected 226 genes (Supplementary Table
1, Supporting Information) that included well-known autoan-
tigen proteins and proteins coded by genes in the mouse
autoimmune susceptibility loci
26 from the mouse full-length
cDNA resource (FANTOM).
27,28 For biotinylation, a bls was
fused onto 5′ site of a target gene by “split-primer” PCR.
13 Using
the PCR, 222 (98.2%) out of 226 genes were successfully
ampliﬁed and of those, 217 (96%) were transcribed. Synthesis
of biotinylated proteins was performed on the GenDecod-
er1000,
19 and expression conﬁrmed by SDS-PAGE combined
with immunoblot analysis using Alexa488-STA (Figure 3B).
Finally 214 clones (94.6%) were produced as biotinylated
proteins (Supplementary Table 1, Supporting Information) at
maximum and minimum concentrations of 500 and 10 nM
respectively (data not shown). From our results in Figure 2B,
the immunoresponse of biotinylated proteins could be detected
below 0.2 nM by the luminescence method, indicating that all
214 proteins are at concentrations viable for screening. There-
fore, we used these proteins as the BPL for screening of
autoantigen proteins.
BPL-Based Screening of Autoantigen Proteins Using the
MRL/lpr Mouse Sera. To identify autoantigen proteins reacting
with antibodies in serum of autoimmune disease mice, the BPL
and sera from pools of MRL/lpr or normal mouse sera (NMS)
Figure 2. Detection of autoantibodies against Hars and LmnB2
proteins. (A) Biotinylated histidyl-tRNA synthetase (Hars) (lane
1), and lamin B2 (LmnB2) (lane 2) and DHFR (lane 3) proteins
were detected by immunoblotting analysis using Alexa488-STA.
M indicates protein molecular weight marker. (B) Various vol-
umes (0.003 to 4 µL: representing 2.5-3280 nM Hars, 1.8-2400
nM LmnB2 and 6.4-8520 nM DHFR) of translation mixture
expressing biotinylated Hars, LmnB2 or DHFR proteins were
incubated with serum of MRL/lpr mouse sera (ﬁnal 1:1000
dilution) in 25 µL of reaction volume. (C) Serum dilution between
1:100 and 1:10 000 was incubated with 1 µL of the translation
mixtures in 25 µL of reaction volume.
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expressing biotinylated protein was incubated with either
serum for 30 min, and subsequently a mixture of donor and
acceptor beads was added to each well (see Figure 1B). After
incubation, antigen-antibody reaction of the BPL was detected
by the luminescence assay as described above. As shown in
the scatter plot (Figure 3C), the intensity of paired luminescent
signals in each well of two independent screening data sets
(plate 1 and 2) using MRL/lpr mouse sera showed a linear
distribution with a R2 of 0.963, indicating reproducibly sufﬁcient
score for screening. We then compared the luminescent signals
of the BPL reacted with MRL/lpr sera and NMS (Figure 3D). In
this assay, only 141 of the 214 proteins in the BPL were
identiﬁed as positive clones, which was indicated by a lumi-
nescence signal 5-fold higher than the average background
signal. Only 96 proteins in the 141 positive clones reacted with
MRL/lpr sera, whereas the remaining 45 proteins interacted
with both sera. From these results, 96 proteins were identiﬁed
as autoantigen proteins in MRL/lpr mice (Table 1, upper left
panel in Figure 3D). In these MRL/lpr autoantigen proteins,
25 well-known autoantigens were included, and 71 out of 96
clones were coded in the genetic loci on chromosome 10; 40
cM, chromosome 15; 18 cM and chromosome 19; 49 cM,
26
indicating that this screening identiﬁed new MRL/lpr sera
Figure 3. BPL-based screening of autoantigen proteins using the MRL/lpr mouse sera. (A) Schematic of the BPL-based screening method.
(B) Thirty-two randomly selected biotinylated proteins of the BPL were detected by immunoblotting analysis using Alexa488-STA. (C)
Scatter plot showing the luminescent signals in each well of two independent screening data sets using MRL/lpr mouse sera. The
x-axis indicates luminescence signals in MRL/lpr plate 1 whereas the y-axis represents those in MRL/lpr plate 2. (D) Each data point
represents luminescence signals using MRL/lpr mouse sera or normal mouse sera (NMS). The x-axis indicates luminescence signals
in NMS whereas the y-axis represents those in MRL/lpr mice. (E, F) Ninety-six proteins identiﬁed as autoantigen proteins were grouped
by protein localization in cells (E) Membrane (GO:0016020), Nucleus (GO:0005634), Cytoplasm (GO:0005737), Extracellular region (GO:
0005576) and Mitochondrion (GO:0005739) and biological function/process (F) Kinase activity (GO:0016301), Peptidase activity (GO:
0008233), Ubiquitin (GO:0005551), Translation (GO:0006412) and Transcription (GO:0006350) according to Gene Ontology Database.
Minor groups less than 3 proteins were belonged to “Other” group. More detailed information on individual proteins was indicated in
the Table 1.
technical notes Matsuoka et al.
4268 Journal of Proteome Research • Vol. 9, No. 8, 2010Table 1. List of 96 Identiﬁed Proteins As Autoantigen Proteins
Gene Ontology
c
gene symbol source
a Mw (kDa) MRL/lpr
b NMS
b cellular location biological function/process
Agpat3 Chr 10_40 43.3 49.7 2.6 Me
Bcr Chr 10_40 35.3 6.4 1.5 K
Unc5b Chr 10_40 103.7 42.3 3.6 Me
Pyp Chr 10_40 33.0 6.3 1.3
Cdc2a Chr 10_40 34.1 11.9 3.6 N K
Cnnm2 Chr 19_49 96.6 64.4 4.4 Me
Thop1 Chr 10_40 78.0 38.9 2.3 C K, P
Hhex
d Chr 19_49 30.0 54.7 1.9 N Tc
Palm Chr 10_40 41.6 59.4 4.1 C, Me
Gnaz Chr 10_40 40.8 72.2 5.0 Me
2610028F08Rik Chr 15_18 28.3 17.9 1.7
Ank Chr 15_18 54.3 55.7 1.7 Me
Nov Chr 15_18 38.8 20.4 1.5 E
Neurl Chr 19_49 36.0 58.0 4.8
Gpam Chr 19_49 93.4 54.2 2.6 Mi, Me
Ncald Chr 15_18 22.2 5.9 1.1
Wnt8b Chr 19_49 40.5 13.8 2.7 E
Timp3 Chr 10_40 24.2 19.8 2.3 Me, E K
Osr2 Chr 15_18 30.6 17.2 1.5 N
Nnp1 Chr 10_40 54.6 51.3 3.7
Nﬁc Chr 10_40 48.8 80.4 3.2 N Tc
Pfkl Chr 10_40 85.4 8.3 3.1 C K
Slc18a2 Chr 19_49 55.8 72.5 2.5 C, Me
Sgta
d Chr 10_40 34.2 23.0 1.3
Hps6 Chr 19_49 87.3 59.5 3.4
Sgpl1 Chr 10_40 63.7 90.9 4.0 Me
Pdxk Chr 10_40 35.1 8.1 1.0 C K
Pwp2h Chr 10_40 102.9 36.3 2.7
Psap Chr 10_40 61.1 42.2 2.4 Mi, E
Fzd6 Chr 15_18 79.1 92.0 2.6 Me
Ilvbl Chr 10_40 68.2 45.8 3.0 Me
Itgb2 Chr 10_40 84.9 41.7 2.9 Me
Cstb Chr 10_40 11.0 18.9 1.4 N, C
Gstt2 Chr 10_40 27.6 25.1 1.3 N, C
Bsg Chr 10_40 29.7 20.4 1.3 Me
Cpn1 Chr 19_49 52.1 6.1 1.0 E P
Eif3s6 Chr 15_18 52.0 8.7 1.2
Timm9 Chr 10_40 10.4 14.2 2.2 Mi, Me
Ndufs7 Chr 10_40 24.7 11.8 2.9 Mi, Me
Psd Chr 19_49 12.4 51.6 2.4 Me
Tfam Chr 10_40 28.0 17.8 2.0 N, Mi Tc
Ppap2c Chr 10_40 31.2 51.2 1.6 Me
Gpx4 Chr 10_40 22.1 18.1 1.5 N, C, Mi, Me
Pcbd1 Chr 10_40 12.0 44.4 2.0 N, C Tc
Ins1 Chr 19_49 12.2 30.1 1.9 E
Mrpl54 Chr 10_40 15.4 8.5 1.0 Mi
Oaz1 Chr 10_40 25.1 11.4 1.3
Cxxc6 Chr 10_40 25.6 32.1 1.5
Sdc2 Chr 15_18 22.1 42.5 2.0 Me
Npm3 Chr 19_49 19.0 13.1 1.2 N Tc
Eif4ebp2 Chr 10_40 12.9 7.6 1.0 Tl
Ddt Chr 10_40 13.1 5.1 0.9 C
Pah Chr 10_40 51.8 32.1 2.2
Peo1 Chr 19_49 77.0 6.8 0.9 Mi
Cabin1 Chr 10_40 65.2 13.8 1.3 N
Lilrb4 Chr 10_40 37.5 9.0 1.4 Me
Casp7 Chr 19_49 34.1 7.6 1.3 C P
Matk Chr 10_40 53.6 72.9 4.0 C, Me K
Egr2 Chr 10_40 49.8 74.7 3.2 N Tc
Slc1a6
d Chr 10_40 60.8 126.0 2.7 Me
Adn Chr 10_40 28.1 63.8 3.1
Gna11 Chr 10_40 42.0 69.7 4.7
Tbxa2r Chr 10_40 37.1 43.9 1.8 Me
Trhr Chr 15_18 44.6 188.7 3.5 Me
Ube2g2 Chr 10_40 33.0 16.0 1.8 U, Tl
Madcam1 Chr 10_40 43.6 33.5 1.8 Me
Pcdh15 Chr 10_40 129.9 70.6 2.6 C, Me
Efna2 Chr 10_40 23.6 5.3 1.0 Me
Sema5a Chr 15_18 120.3 19.1 1.8 Me
Aire Chr 10_40 18.0 8.6 1.2 N, C Tc, Tl
Fgf8 Chr 19_49 24.7 11.1 1.8 E
Snrpd2 AA* 13.6 13.4 3.3 N
Hmgn2 AA 9.4 85.7 2.2 N, C
Mcrs1 AA 51.7 45.5 3.2 N
Hnrpa2b1 AA 32.5 19.5 2.1
Hars AA 57.4 104.9 4.8 C Tl
Rpo1-3 AA* 15.1 6.4 4.2
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reported as the susceptibility loci of arthritis. Furthermore,
according to Gene Ontology (GO) Database (http://www.
geneontology.org/), 73 (76%) of the proteins were classiﬁed by
cellular localization (Figure 3E) and 25 (26%) classiﬁed by
biological function/process (Figure 3F). The annotated proteins
found were classiﬁed as localized with Membrane (22%),
Membrane/Cytoplasm (4%), Extracellular space (7%), Nucleus
(13%), Nucleus/Cytoplasm (13%), Cytoplasm (7%) and Mito-
chondrion (2%). Also, the annotated proteins were involved in
diverse biological functions/processes such as Kinase activity
(8%), Kinase activity/peptidase activity (1%), transcription (8%),
Transcription/Translation (1%), Translation (3%), Ubiquitin/
Translation (1%) and Peptidase activity (3%). Data analysis
showed that 26 and 25 proteins were annotated in localization
of nucleus and cytoplasm respectively (Figure 3E, Table 1), and
that 9 and 9 proteins were related to cellular events of protein
phosphorylation and transcription, respectively (Figure 3F,
Table 1). Many nuclear proteins were reported as autoantigens.
2
Interestingly, localization of 38 (39.6%) antigen proteins react-
ing with antibodies in MRL/lpr mouse sera was annotated in
membrane and/or extracellular space. These results suggest
that the wheat cell-free system is a viable platform to study
folded membrane proteins that function as antigens. The data
analysis suggests that MRL/lpr autoantigen proteins are rep-
resented by a wide variety of biological functions localized in
whole cells, rather than just nuclear proteins. Taken together,
these results indicate that the BPL-based screening method
would be useful for identiﬁcation of autoantigen proteins.
Validation of Identiﬁed Autoantigen Proteins by Immunob-
lotting and Immunoprecipitation. Recent reports have men-
tioned the possibility that autoantibodies may react with
conformational epitopes.
29-31 These data were obtained by
liquid phase immunoprecipitation assays using recombinant
proteins.
32,33 Under these situations, autoantigen proteins we
found were analyzed by immunoblotting and immunoprecipi-
tation. For this analysis, six proteins were randomly selected
(see legend in Figure 4). Immunoblot analysis showed that
three proteins reacted with MRL/lpr mouse sera (Lanes 2, 5,
and 6 in Figure 4A). Two of these three proteins, LmnB2 (Lane
5) and topoisomerase II alpha (Top2a) (Lane 6), have been well
characterized as autoantigen proteins so far.
22,34 Also, six of
our identiﬁed autoantigen proteins were not detected by
immunoblot analysis in the sera of NMS (data not shown).
Interestingly, immunoprecipitation analysis revealed antige-
nicity of all six autoantigen proteins (Figure 4B, C), whereas
two proteins randomly selected from nonautoantigen proteins,
serving as a negative control, did not show signiﬁcant reaction
to the sera from MRL/lpr mice by both immunoblot analysis
and immunoprecipitation (Lanes 7 and 8 in Figure 4A, B). These
results suggest that the BPL-based screening method may be
useful for identiﬁcation of autoantigen proteins reacting with
autoantibodies recognizing conformational epitopes.
Discussion
To address high-throughput protein production, we have
utilized our wheat germ high-throughput protein synthesis
system,
10,16 which can produce large numbers of recombinant
proteins using a fully automated robot.
19 To create a library of
target autoantigen proteins, full-length human and mouse
cDNA resources were provided by the Mammalian Gene
Collection (MGC) clones (Mammalian Gene Collection Pro-
gram, http://mgc.nci.nih.gov/) and FANTOM.
27,28 Since the
full-length cDNA was provided in plasmids, no additional time-
consuming cloning steps were needed for the synthesis of linear
DNA templates by PCR for direct entry into the cell-free based
protein production system. Additionally, researchers can select
and use any appropriate peptide tag for downstream applica-
tions, like a bls used in this study, owing to the ease of template
construction. In fact, given the advantages of the gateway
system and PCR, a recent publication reported successful
production of 13 000 His-tagged human proteins by the wheat
cell-free system using full-length cDNA resources.
12 Further-
more, because protein puriﬁcation is a time-consuming-step,
an assay system with no puriﬁcation requirement could
dramatically increase the throughput. For that, a speciﬁc
Table 1. Continued
Gene Ontology
c
gene symbol source
a Mw (kDa) MRL/lpr
b NMS
b cellular location biological function/process
Hars2 AA* 23.4 7.3 1.6 C, Mi Tl
Hspca AA 84.8 5.9 3.1
Vtn AA 54.8 5.8 1.6 E
Snrpd3 AA* 13.9 10.2 2.8 N, C
Hmgn1 AA* 10.1 35.6 4.5 N, C Tc
Rnps1 AA 40.8 26.0 1.4 N, C
Fbl AA 34.2 24.9 1.9 N
Npm1 AA 32.6 12.6 1.1 N, C K
Top3b AA* 96.9 18.9 2.6
Coil AA 62.2 9.8 1.6 N
Casp8 AA 55.4 27.5 2.8 N, C P
Ybx1 AA 35.7 27.8 4.7 N, C Tc
Srpk1 AA 73.1 17.7 3.8 N, C K
Rpa1 AA 71.4 36.6 3.8 N
Car9 AA* 47.3 8.9 1.5 Me
Sag AA 44.9 11.9 2.2
Dnahc8 AA 122.1 9.2 1.6 C
Top3a AA* 107.0 13.1 2.0
Fbn2 AA 56.6 5.9 1.4 E
a The source of selected gene done by symbol, is as follows: Chr 10_40, genetic loci on chromosome 10_40 cM; Chr 15_18, genetic loci on chromosome
15_18 cM; Chr 19_49, genetic loci on chromosome 19_49 cM; AA, well-known autoantigen; AA*, well-known autoantigen homologue.
b Relative
luminescence signals.
c According to Gene Ontology (GO) Database (http://www.geneontology.org/), the proteins were classiﬁed by cellular localization
and biological function/process, is as follows: Me, Membrane (GO:0016020); N, Nucleus (GO:0005634); C, Cytoplasm (GO:0005737); E, Extracellular region
(GO:0005576); Mi, Mitochondrion (GO:0005739); K, Kinase activity (GO:0016301); P, Peptidase activity (GO:0008233); U, Ubiquitin (GO:0005551); Tl,
Translation (GO:0006412); Tc, Transcription (GO:0006350).
d Hhex, lane1; Sgta, lane3; Slc1a6, lane4 in Figure 4.
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4270 Journal of Proteome Research • Vol. 9, No. 8, 2010Figure 4. Detection of identiﬁed autoantigen proteins by immunoblotting and immunoprecipitation. (A) Immunoblotting analysis by
using recombinant proteins. Puriﬁed recombinant proteins were separated by SDS-PAGE and stained with CBB (Upper). Puriﬁed
recombinant proteins were reacted with serum from MRL/lpr mouse (Lower). (B) Immunoprecipitation analysis using recombinant
proteins. Translation mixtures expressing biotinylated proteins were incubated with 1 µL of undiluted serum overnight at 4 °C.
Immobilized Protein A sepharose was added to each sample, and incubated for 60 min at 4 °C. After washing, proteins were separated
by SDS-PAGE, followed by immunoblotting with Alexa488-STA. M indicates a 45 kDa protein molecular weight marker. (C) Whole data
of randomly selected proteins. IB, Immunoblotting; IP, Immunoprecipitation. Relative luminescence signal, 102 e ++;5e + < 102; -
< 5. (A, B, C) Lane 1, Hhex; Lane 2, Tdg; Lane 3, Sgta; Lane 4, Slc1a6; Lane 5, Lmnb2; Lane 6, Top2a; Lane 7, Cs; Lane 8, Car4. Lane 7
and 8 were negative controls. Detailed information on individual proteins was indicated in Supplementary Table 1 (Supporting
Information).
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tion. In this study, we selected biotin as our target protein label
due to the highly speciﬁc binding of biotin-streptavidin.
Commonly, biotinylated proteins are produced via NHS ester-
activated biotins. However, this technique requires laborious
puriﬁcation to remove any nonreacted biotin reagent in the
reaction mixture. Therefore, we used a BirA biotin-ligase-based
labeling system. By addition of BirA and biotin to the wheat
cell-free system, highly speciﬁc biotin-labeling is available and
the biotinylated proteins can be directly used for assaying
13,15,35
without further puriﬁcation. Taken together, the biotinylated
protein library produced by the wheat cell-free system is
suitable for autoantigen screening.
Several autoantigen screening methods such as SERPA,
SEREX and protein microarray are currently widely used for
identiﬁcation of autoantigen proteins, each of which has
inherent limitations. In this study, we demonstrated improved
methodologies that overcome the aforementioned limitations
using a wheat cell-free based BPL and luminescence assay that
allow detection of autoantigen proteins with autoantibodies in
sera. The BPL-based screening revealed that speciﬁc antibody
interaction were detected at subpicogram scale, with a linear
response over a 1000-fold range, and appear to be more
sensitive than conventional method, such as ELISA.
6,36 It should
be noted that protein microarray could also detect autoantigen
at picogram scale, in the linear fashion over a 1000-fold range.
6
While the detection sensitivity of the BPL-based autoantigen
protein screening method might be equivalent to microarray
based autoantigen protein screening, the folded state of the
autoantigen proteins differs. The reports which autoantibodies
would recognize conformational epitopes
29,30 might contain an
important implication for screening of autoantigen proteins.
Although conventional methods use denatured or unfolded
proteins, such as dehydrated or detergent-treated proteins,
the BPL-based method tested in this study better represents
the folded, native form as all procedures are carried out in the
solution phase without dehydration or detergent treatment. In
addition, the BPL-based screening method using serum dilu-
tions of 1:10 000 could produce high luminescent signal in 25
µL of reaction volume (Figure 2C). Thus, 50 µL of serum would
be sufﬁcient to screen 20 000 kinds of human proteins.
Autoimmune diseases were thought to be a complex of both
genetic and nongenetic factors inﬂuencing susceptibility, sever-
ity and response to therapies.
37 Twin and family studies suggest
that approximately 60% of susceptibility is due to genetic
factors and genes within the HLA locus, particularly HLA-DRB1,
which accounts for almost half of the genetic component of
susceptibility.
37 Also, genetic analyses identiﬁed that other
susceptibility locus of RA, SLE, and so on.
38 In this study, we
screened proteins encoded by genes on an autoimmune sus-
ceptibility loci,
26 and 71 out of 111 clones (Table 1 and
Supplementary Table 1, Supporting Information) localized on
the chromosomes 10, 15 and 19
26 were found as new autoan-
tigen proteins reacting with the sera of MRL/lpr mice. Ad-
ditionally, the Gene Ontology (GO) Database may be extremely
useful for the screening of autoantigen protein. For example,
based on data from the GO Database, localization of 38 (39.6%)
autoantigen proteins out of 96 MRL/lpr autoantigen proteins
were annotated in membrane and/or extracellular space (Figure
3E). These results suggest that a speciﬁc protein library focused
on the human autoimmune susceptibility loci and membrane
proteins or extracellular spaces classiﬁed according to GO
Database may be a good target for screening of autoantigen
proteins.
A key obstacle for robust genome-wide screening has been
experimentally simple techniques and automated technology.
The BPL-based screening method is one of the simplest
approaches for identiﬁcation of autoantigen proteins, because
all experimental processes, including construction of DNA
templates,andinteractionanddetectionofantigen-autoantibodies
reactions, were reduced to mixing steps. Synthesis of the
biotinylated protein library was accomplished using a fully
automated robot,
19 and the biotinylated proteins can be used
in subsequent screening steps without puriﬁcation. The method
described here can be used in developed for use in 96, 384
(Figure 3A) or 1536-well microtiter-plate format through the
use of appropriate automated liquid handling robots. Therefore
this method is suitable for development of a genome-wide
screening platform. In conclusion, the BPL-based screening
method has a high potential for identiﬁcation of autoantigen
proteins in human autoimmune diseases.
Abbreviations: Alexa488-STA, streptavidin Alexa Fluor 488
conjugate; NMS, normal mouse sera; SEREX, serological ex-
pression cloning; SERPA, serological proteome analysis; bls,
biotin ligation site; DHFR, dihydrofolate reductase; Lmnb2,
lamin B2; Hars, histidyl-tRNA synthetase; Top2a, topoisomerase
II alpha; Hhex, hematopoietically expressed homeobox; Tdg,
thymine DNA glycosylase; Sgta, small glutamine-rich tetratri-
copeptide repeat (TPR)-containing, alpha; Slc1a6, solute carrier
family 1 (high afﬁnity aspartate/glutamate transporter), mem-
ber 6; Cs, citrate synthase; Car4, carbonic anhydrase 4; BPL,
biotinylated protein library; FANTOM, functional annotation
of mouse; CBB, coomassie brilliant blue; RF, rheumatoid factor;
hnRNP, heterogeneous nuclear ribonucleoprotein; Sm, Smith;
GO, Gene Ontology; NHS, N-hydroxysuccinimide; RA, rheu-
matoid arthritis; SLE, systemic lupus erythematosus; MRL/lpr,
MRL/Mp-lpr/lpr.
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